GHRP-6 5mg

GHRP-6 5mg — Research Overview

Synthesised in the early 1980s, GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the original GH secretagogues developed for research. It is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) that acts as a potent agonist at the ghrelin receptor (GHS-R1a), triggering GH release from pituitary somatotrophs. While GHRH analogues work upstream to boost somatotroph cAMP and gene transcription, GHRP-6 uses the GHS-R1a/Gq/IP3 pathway to trigger GH vesicle exocytosis directly. Its early characterisation actually helped define the GH secretagogue receptor pathway decades before ghrelin was even identified as the endogenous ligand.

Mechanism of Action

GHRP-6 binds GHS-R1a and activates phospholipase C through Gq coupling, raising intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum while DAG activates PKC. These signals work together to drive GH vesicle fusion and exocytosis. The resulting GH pulse is rapid and short-lived. It is a profile that’s consistent with the short plasma half-life GHRP-6 shows in vivo.

GHRP-6 also kicks appetite into gear, which makes sense given how closely it’s related to ghrelin. Since GHS-R1a is expressed on neuropeptide Y/AgRP neurons in the hypothalamus’s arcuate nucleus—the main orexigenic circuit—GHRP-6’s activation of these neurons drives the hunger response seen in animal models. This sets it apart from more selective secretagogues like Ipamorelin 2mg, which barely touches appetite at all, and gives GHRP-6 a pharmacological profile much closer to native ghrelin.

Research Context

GHRP-6 has one of the longest research histories of any GH secretagogue, so it’s often the standard reference point for comparing newer compounds. Its well-characterised pharmacokinetics, receptor binding affinity, and GH-stimulating potency in rodent and human studies provide a solid baseline for comparative experiments. When researchers study GHRP-2 5mg and Hexarelin 2mg, they’ll frequently use GHRP-6 as the benchmark GHS compound.

GHRP-6 does more than just secrete GH; it’s also caught the eye of researchers for its potential to protect cardiac and GI tissues directly. Studies using rodent models of cardiac ischemia show that GHRP-6 can actually shrink infarct size and lower inflammatory cell infiltration. Interestingly, these mechanisms seem to work somewhat independently of GH secretion. This mirrors what’s been seen with hexarelin, backing the idea that activating GHS-R1a or CD36 might offer direct protection to these tissues.

When paired with GHRH analogues like CJC-1295 W/O DAC or Sermorelin 2mg, GHRP-6 triggers a synergistic GH release in both rodent and human models. This makes it a valuable tool for studies focused on pushing somatotropic axis output to its limit for metabolic or anabolic research.

Laboratory Handling

GHRP-6 5mg comes as a lyophilised powder. Researchers usually reconstitute it with sterile bacteriostatic water. Reconstituted solutions are stored at 4°C for use within a few days, or aliquoted for storage at −20°C. Exposure to room temperature and repeated freeze-thaw cycles should be avoided. It is advisable to verify purity via HPLC before starting experiments.

This product is for research purposes only. It’s not intended for clinical or therapeutic use.

References

• Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. 1984;114(5):1537–1545.
• Frieboes RM, et al. Growth hormone-releasing peptide-6 promotes sleep and suppresses sleep-related growth hormone release in normal and in growth hormone-deficient children. J Neuroendocrinol. 1995;7(8):589–594.
• Granado M, et al. Ghrelin and GHRP-6 decrease the expression of inflammatory cytokines in a model of endotoxemia. Mol Cell Endocrinol. 2005;229(1–2):129–138.
• Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. 1996;273(5277):974–977.

Comparative Notes

Researchers should keep in mind that GHRP-6 has a strong appetite-stimulating effect, which can easily mess up body composition data if food intake isn’t strictly controlled. If a study aims to look at GH-mediated metabolic changes on their own, the extra calories GHRP-6 triggers might change body weight and fat levels independently. To fix this, scientists often use pair-feeding designs or switch to a more selective secretagogue like ipamorelin — which doesn’t really affect appetite — to keep these variables separate in preclinical metabolic research.

For more information on GHRP-6 please visit Wikipedia.